股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 東曜藥業股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01875 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | | 已發行股份總數 | | | 上月底結存 | | | 772,787,887 | | | 0 | | 772,787,887 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月底結存 | | | 772,787,887 | | | 0 | | ...

BioDlink International Company Limited 根據自2023年12月31日起生效的香港聯合交易所有限公司證券上市規則（「上市規則」）（經修訂）、於2025年4月17日生效的公 司條例（香港法例第622章）及2025年公司（修訂）條例，以及本公司經修訂及重列的組織章程細則，本公司已採納以電子形式 發佈本公司日後的公司通訊（「公司通訊」） （附註2） 之新安排。所有日後的公司通訊，包括英文及中文版本，均透過本公司網站 www.biodlink.com 及香港聯合交易所有限公司（「聯交所」）網站www.hkexnews.hk（「網站版本」）以電子形式向非登記股東提供 並僅會於個別非登記股東要求時才向其發送印刷本。 閣下可在本公司網站「投資者關係」項下「信息披露」取覽公司通訊。 本公司不會向 閣下發送公司通訊之網站版本的登載通知。本公司鼓勵股東主動留意網站上所有日後的公司通訊的登載情 況，並自行取覽公司通訊之網站版本。 我們鼓勵 閣下於本公司網站以電子形式取覽公司通訊。如 閣下希望收取日後的公司通訊之印刷版，請填妥本函背頁之 申請表格並交回本公司的股份過戶登記處（「股份過戶登記處」）卓 ...

BioDlink International Company Limited 東曜藥業股份有限公司 （於香港註冊成立的有限公司） （股份代號：1875） 登記股東之名稱及地址 致股東： 發佈公司通訊之新安排 簡介 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第2.07A條（經修訂） 1 、於2025年4月17日 生效的公司條例（香港法例第622章）及2025年公司（修訂）條例，以及東曜藥業股份有限公司（「本公司」）經修訂 及重列的組織章程細則，本公司將以電子形式向其股東（3「股東」）發佈本公司日後的公司通訊（「公司通訊」2）， 並僅應股東要求向其發送公司通訊之印刷本。 就此而言，以下安排將於2025年8月15日（星期五）生效。請注意， 閣下過往就接收公司通訊方式向本公司或本 公司股份過戶登記處作出之任何指示均已失效。 安排 1. 可供採取行動的公司通訊4 本公司將以電子形式透過電郵向股東個別地發送可供採取行動的公司通訊。如本公司未獲取股東的電郵 地址或其提供的電郵地址無效5，本公司將向其發送可供採取行動的公司通訊之印刷本，連同一份索取股 東有效電郵地址的表格，以便將來以電子形式發佈可供 ...

本文源自：金融界AI电报 东曜药业-B(01875.HK)公布2025年中期业绩，营收约4.89亿元，净利润约406.2万元。经营活动现金净额 持续为正，2025年上半年为3483万元，同比上升25%。 ...

Group 1: Financial Performance - The company reported a revenue of approximately 489 million RMB and a net profit of about 4.062 million RMB for the first half of 2025 [1] - The net cash flow from operating activities remained positive, amounting to 34.83 million RMB, representing a year-on-year increase of 25% [1] Group 2: Business Strategy and Growth - Since the strategic transformation to CDMO, the company has become a leading domestic biopharmaceutical CDMO provider, offering comprehensive international services from R&D to commercial production [1] - In the first half of 2025, the company added 16 new projects, including 14 ADC projects, bringing the total to 169 projects, and assisted 12 projects in advancing from preclinical to clinical stages [1] - The company has a signed but unfulfilled order backlog of 200 million RMB, indicating strong future revenue potential [1] - The company achieved a repurchase rate of 73% during the reporting period, reflecting high customer satisfaction and service quality [1] Group 3: Product Development and International Expansion - The core product, Bevacizumab injection (domestic brand name: Puxintin), has made significant progress in overseas expansion in emerging markets, successfully obtaining market approval in Nigeria and Pakistan [2] - As of June 30, 2025, the company's facilities have passed GMP inspections in Brazil, Colombia, Egypt, Indonesia, Argentina, and Pakistan, demonstrating international recognition of its quality system and compliance [2] - The approvals in Nigeria and Pakistan mark a breakthrough for the company in international commercial supply, enhancing its global market presence [2]

Group 1 - The company reported a revenue of approximately 489 million RMB and a net profit of about 4.06 million RMB for the first half of 2025, with a positive net cash flow from operating activities of 34.83 million RMB, representing a 25% year-on-year increase [1] - Since its strategic transformation to CDMO, the company has become a leading domestic biopharmaceutical CDMO provider, offering comprehensive international services from R&D to commercial production for various bioconjugates [1] - As of June 30, 2025, the company added 16 new projects in the first half of the year, including 14 ADC projects, bringing the total to 169 projects, and assisted 12 projects in advancing from preclinical to clinical stages, showcasing its service delivery capabilities [1] - The company has signed uncompleted orders amounting to 200 million RMB, with a repurchase rate of 73% due to its excellent delivery capabilities and service quality [1] - The company successfully assisted clients in completing the world's first approved clinical dual-load ADC project during the reporting period [1] Group 2 - The company's core product, Bevacizumab injection (domestic brand name: Puxintin®), has made significant progress in overseas expansion in emerging markets, successfully obtaining market approval from regulatory authorities in Nigeria and Pakistan in the first half of 2025 [2] - Facilities related to the product have passed GMP inspections in Brazil, Colombia, Egypt, Indonesia, Argentina, and Pakistan, indicating international recognition of the company's quality system and compliance [2] - The approvals in Nigeria and Pakistan mark a breakthrough for the company in international commercial supply, as it will be responsible for the global commercialization of Bevacizumab injection [2]

[Performance Summary](index=1&type=section&id=Performance%20Summary) [Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) In H1 2025, total revenue decreased by 6% to RMB 489 million, with product sales slightly down and CDMO/CMO revenue falling 32% due to project delays, leading to an 87% drop in net profit to RMB 4.06 million, while operating cash flow grew 25% to RMB 34.83 million, and core product Bevacizumab Injection made significant overseas market progress Key Financial Indicators for H1 2025 | Indicator | H1 2025 (RMB Thousands) | YoY Change | | :--- | :--- | :--- | | Revenue | 489,140 | -6% | | - Product Sales Revenue | 397,909 | -1% | | - CDMO/CMO Business Revenue | 77,301 | -32% | | Net Profit | 4,062 | -87% | | Net Cash from Operating Activities | 34,830 | +25% | - The decline in net profit is primarily attributed to delayed delivery milestones for key CDMO projects, increased depreciation and amortization from new major construction projects, and higher selling and administrative expenses for overseas market expansion and management system optimization[4](index=4&type=chunk) - Core product Bevacizumab Injection (Puxinting®) received marketing approval in Nigeria and Pakistan, with production facilities passing GMP inspections in Brazil, Colombia, and other countries, marking the commencement of the company's international commercial supply[5](index=5&type=chunk) - The company-licensed TAB014 (Bevacizumab Intravitreal Injection Solution) to Zhaoke Ophthalmology has submitted a marketing application, making it the first Bevacizumab ophthalmic formulation to be declared for marketing in China for wet age-related macular degeneration (wAMD)[6](index=6&type=chunk) [Consolidated Financial Information](index=3&type=section&id=Consolidated%20Financial%20Information) [Interim Condensed Consolidated Statement of Comprehensive Income](index=3&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Comprehensive%20Income) For the six months ended June 30, 2025, the company reported revenue of RMB 489 million, a 6% decrease year-on-year, with operating profit significantly dropping to RMB 9.18 million from RMB 33.26 million due to stable costs and expenses amidst declining revenue, resulting in a net profit of RMB 4.06 million, down 87% year-on-year, and basic and diluted earnings per share of RMB 0.01 Summary of Interim Condensed Consolidated Statement of Comprehensive Income (For the six months ended June 30) | Item | 2025 (RMB Thousands) | 2024 (RMB Thousands) | YoY Change | | :--- | :--- | :--- | :--- | | Revenue | 489,140 | 520,603 | -6.0% | | Operating Profit | 9,178 | 33,258 | -72.4% | | Profit Before Income Tax | 4,062 | 31,559 | -87.1% | | Profit for the Period | 4,062 | 31,559 | -87.1% | | Basic and Diluted Earnings Per Share (RMB) | 0.01 | 0.04 | -75.0% | [Interim Condensed Consolidated Statement of Financial Position](index=4&type=section&id=Interim%20Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, total assets were RMB 1.476 billion, a slight decrease from year-end 2024, while total liabilities decreased to RMB 745 million, primarily due to lower current liabilities, and total equity slightly increased to RMB 732 million, with net current assets improving to RMB 390 million from RMB 328 million Summary of Interim Condensed Consolidated Statement of Financial Position | Item | June 30, 2025 (RMB Thousands) | December 31, 2024 (RMB Thousands) | | :--- | :--- | :--- | | **Total Assets** | **1,476,422** | **1,508,772** | | Non-current Assets | 729,669 | 765,495 | | Current Assets | 746,753 | 743,277 | | **Total Liabilities** | **744,740** | **779,117** | | Non-current Liabilities | 388,247 | 363,754 | | Current Liabilities | 356,493 | 415,363 | | **Total Equity** | **731,682** | **729,655** | | Net Current Assets | 390,260 | 327,914 | [Notes to Financial Information](index=6&type=section&id=Notes%20to%20Financial%20Information) The notes detail the company's accounting policies, revenue composition, and asset and liability status, showing that product sales constitute the largest portion of revenue, the vast majority of income and non-current assets are from Mainland China, total borrowings are approximately RMB 396 million with a weighted average effective interest rate of 3.33%, and no dividends were distributed this period Revenue Breakdown for H1 2025 (RMB Thousands) | Revenue Category | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Sales of Goods | 397,909 | 400,400 | | CDMO/CMO | 77,301 | 113,791 | | Commission Income | 6,144 | 5,339 | | Revenue from Licensed-out Products | 4,717 | – | | Others | 3,069 | 1,073 | | **Total** | **489,140** | **520,603** | - The company's operations are primarily concentrated in Mainland China, with 97.5% of total revenue in H1 2025 originating from Mainland China, and all non-current assets located there[26](index=26&type=chunk) - As of June 30, 2025, the company's total borrowings amounted to **RMB 396 million**, with approximately 90% being non-current (over one year) borrowings, and the weighted average effective interest rate for bank borrowings was **3.33%**[38](index=38&type=chunk)[40](index=40&type=chunk) - The Board resolved not to declare an interim dividend for the six months ended June 30, 2025[44](index=44&type=chunk) [Management Discussion and Analysis](index=16&type=section&id=Management%20Discussion%20and%20Analysis) [Business Review](index=16&type=section&id=Business%20Review) In H1 2025, the company solidified its position as a leading domestic biopharmaceutical CDMO, particularly in the ADC field, adding 16 new projects, accumulating 169 projects, securing RMB 200 million in signed uncompleted orders with a 73% customer repurchase rate, while its self-developed core product Puxinting® (Bevacizumab) achieved significant overseas expansion with approvals in Nigeria and Pakistan, initiating international commercial supply - As a one-stop, integrated, end-to-end antibody and ADC drug CDMO service provider, the company added **16 new projects** (including 14 ADC projects) in H1, accumulating a total of **169 projects**[47](index=47&type=chunk)[48](index=48&type=chunk) - Signed and uncompleted orders reached **RMB 200 million**, with a customer repurchase rate of **73%** during the reporting period, and the company assisted a client in completing the world's first approved clinical dual-payload ADC project[48](index=48&type=chunk) - Core product Puxinting® (Bevacizumab) received marketing approval in Nigeria and Pakistan, with production facilities passing GMP inspections in multiple countries, initiating international commercial supply[50](index=50&type=chunk) [CDMO Business Development and Competitive Advantages](index=19&type=section&id=CDMO%20Business%20Development%20and%20Competitive%20Advantages) The company's CDMO business leverages its "integrated, end-to-end" antibody and ADC industrialization platform to significantly shorten R&D cycles, continuously iterating technology platforms like BDKcell® and GL-DisacLink™ ADC sugar-site conjugation technology, maintaining a quality management system compliant with Chinese, US, and European GMP standards with over 60 audits, and benefiting from flexible capacity deployment and an experienced international core team for differentiated competitive advantages - Offers "integrated, end-to-end" antibody and ADC one-stop CDMO services, capable of shortening the timeline from DNA sequence to IND submission to as fast as **11 months**[56](index=56&type=chunk) - Continuously iterates technology platforms, including the self-developed BDKcell® cell line development platform, and co-develops GL-DisacLink™ ADC sugar-site conjugation technology with partners[57](index=57&type=chunk)[59](index=59&type=chunk) - Quality system complies with international standards, having undergone over **60 GMP audits**, including a zero-deficiency EU QP audit and official GMP inspections from multiple emerging market countries[60](index=60&type=chunk) - The CDMO core team is stable, with key executives averaging over **15 years of multinational enterprise management experience**, and as of June 30, 2025, the CDMO team comprised **524 individuals**, accounting for **87%** of the company's total workforce[62](index=62&type=chunk) [Marketed Products and R&D Pipeline](index=22&type=section&id=Marketed%20Products%20and%20R%26D%20Pipeline) The company is streamlining its R&D pipeline to reduce expenses and focus on its core CDMO business, with Puxinting® (Bevacizumab Injection) and Tizian® (Temozolomide Capsules) as its main commercial products; Puxinting® is a core revenue driver, generating RMB 398 million in domestic sales in H1 2025 and actively pursuing overseas registrations in 35 countries, while Tizian® continues to supply the market through national centralized procurement Status of Key R&D Pipeline | Investigational Drug | Indication | Current Stage | | :--- | :--- | :--- | | TAE020 | Acute Myeloid Leukemia | Clinical Phase I | | TAB014 | Wet Age-related Macular Degeneration | NDA | | TAC020 | Various Solid Tumors | Preclinical | - Core product Puxinting® (Bevacizumab) generated domestic sales revenue of **RMB 398 million** in H1 2025, has initiated marketing registration applications in **35 overseas countries**, and received approvals in Nigeria and Pakistan[65](index=65&type=chunk) - Another marketed product, Tizian® (Temozolomide Capsules), has been included in the National Centralized Drug Procurement list and continues to supply multiple provinces after winning bids[66](index=66&type=chunk) [Financial Position Analysis](index=26&type=section&id=Financial%20Position%20Analysis) In H1 2025, the company's revenue decreased by 6% to RMB 489 million, primarily due to a 32% drop in CDMO business revenue impacted by project delivery milestones, leading to an 87% year-on-year plunge in net profit to RMB 4.06 million due to reduced revenue, increased depreciation and amortization, and higher selling and administrative expenses; R&D expenses decreased by 23% through pipeline streamlining, operating cash flow remained healthy with a 25% increase, and investing cash outflow significantly reduced as project construction neared completion Key Financial Item Changes for H1 2025 (RMB Thousands) | Item | H1 2025 | H1 2024 | Reason for Change | | :--- | :--- | :--- | :--- | | Revenue | 489,140 | 520,603 | Some CDMO projects did not reach delivery milestones | | - Product Sales Revenue | 397,909 | 400,400 | Increased market competition | | - CDMO/CMO Revenue | 77,301 | 113,791 | Significant project milestones completed in prior period | | R&D Expenses | 35,628 | 46,059 | Pipeline streamlining, resources focused on CDMO | | Selling Expenses | 277,445 | 276,482 | Increased investment in overseas market promotion | | General and Administrative Expenses | 34,725 | 32,105 | Company expansion, management system enhancement | | Net Profit | 4,062 | 31,559 | Combined impact of revenue decline and increased expenses | - Net cash inflow from operating activities was **RMB 34.83 million**, a **25%** year-on-year increase, demonstrating effective working capital management[85](index=85&type=chunk) - Net cash outflow from investing activities significantly decreased to **RMB 26.51 million** (from RMB 68.78 million in the prior period), primarily due to the global R&D service center construction project nearing completion[85](index=85&type=chunk) [Other Information](index=30&type=section&id=Other%20Information) [Corporate Governance and Dividends](index=30&type=section&id=Corporate%20Governance%20and%20Dividends) The company's audit committee reviewed the financial statements for the period, the Board resolved not to declare an interim dividend for the six months ended June 30, 2025, and the company complied with the Corporate Governance Code and the Model Code for Securities Transactions by Directors during the reporting period - The Board resolved not to declare an interim dividend for the six months ended June 30, 2025[87](index=87&type=chunk) - The company confirmed compliance with the Corporate Governance Code and the Model Code for Securities Transactions by Directors of Listed Issuers as set out in the Listing Rules throughout the reporting period[88](index=88&type=chunk)[89](index=89&type=chunk) [Use of Proceeds from Subscription](index=30&type=section&id=Use%20of%20Proceeds%20from%20Subscription) The company provided a detailed disclosure on the use of net proceeds from the 2022 subscription, with approximately RMB 20.09 million utilized in H1 2025 and approximately RMB 18.13 million remaining unutilized, which the company intends to use according to previously announced and subsequently revised proposed uses - Regarding the proceeds from the 2022 subscription, approximately **RMB 18.13 million** remained unutilized as of June 30, 2025[94](index=94&type=chunk) - The company plans to utilize the remaining net proceeds according to the disclosed purposes, as revised by reallocations in 2024 and 2025[94](index=94&type=chunk)

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年7月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 東曜藥業股份有限公司 | | | 呈交日期: | 2025年8月5日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 | 1. 股份分類 | | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號(如上市) | | 01875 | | 說明 | | | | | | | | 股份期權計劃詳情 | | 上月底結存的股份期權數 目 | | 本月內變動 | | 本月底結存的股份期權數 目 | 本月內因此發行的新股數 目 (A1) | 本月内因此自庫存轉讓的 庫存股份數目 (A2) | 本月底因此可能發行或自 庫存轉讓的 ...

Core Viewpoint - Dongyao Pharmaceutical-B (01875.HK) has announced a board meeting scheduled for August 12, 2025, to consider and approve the interim results for the six months ending June 30, 2025, along with other matters [1] Summary by Category - **Company Announcement** - The company will hold a board meeting on August 12, 2025, to discuss the interim performance [1] - The meeting will focus on the financial results for the six months ending June 30, 2025 [1] - Other unspecified matters will also be addressed during the meeting [1]

董事會會議召開日期 BioDlink International Company Limited 東曜藥業股份有限公司 （於 香 港 註 冊 成 立 的 有 限 公 司） （股 份 代 號：1875） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 東曜藥業股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董事會（「董 事 會」）茲 通 告，本 公 司 謹 定 於2025年8月12日（星 期 二）舉 行 董 事 會 會 議，以 考 慮 及通過本集團截至2025年6月30日 止 六 個 月 中 期 業 績，以 及 處 理 其 他 事 項。 承董事會命 東曜藥業股份有限公司 劉軍博士 首席執行官兼執行董事 香 港，2025年7月31日 於 本 公 告 日 期，本 公 司 執 行 董 事 為 劉 軍 博 士；本 公 司 非 執 行 董 事 為 付 山 先 生、 黃 純 瑩 女 士 ...